Acorda Therapeutics Company Profile

13:44 EST 23rd November 2017 | BioPortfolio

Acorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial development efforts on a range of therapeutics for individuals with chronic, or long term, SCI. Currently, there is no therapy that improves neurological function in chronic SCI patients.

However, Acorda's clinical stage product, Fampridine-SR, has improved neurological function for patients with chronic SCI in Phase 2 clinical trials. The Company believes that the therapeutic products it develops for SCI are likely also to have applications in other neurological conditions-for example, both Fampridine-SR and the Company's M1 monoclonal antibody ("M1") product have shown promise as therapies for multiple sclerosis ("MS"). Other potential markets for the Company's products include traumatic brain injury, Parkinson's disease and stroke.


15 Skyline Drive
United States of America


Phone: 914-347-4300
Fax: 914-347-4560

News Articles [623 Associated News Articles listed on BioPortfolio]

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / November 17, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. ("Acorda" or the "C...

Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another

Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a...

FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble

The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is cri...

Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study

Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear. Ardsley, NY-based Acord...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acorda Therapeutics, Inc. - ACOR

NEW YORK, Nov. 16, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acorda Therapeutics, Inc.("Acorda" or the "Company") (NASDAQ: ACOR). Such investors are advi...

Parkinson’s drug setback hits Acorda stock hard

More than 24% was taken off the market value of neurological disorders specialist Acorda Therapeutics…

Acorda monetizes Fampyra royalties for $53 million

Acorda Therapeutics, which last week suffered a significant setback with its Phase III program of Parkinson’s…

Acorda axes Parkinson's drug after trial deaths

Acorda Therapeutics has abandoned development of its Parkinson’s drug, tozadenant, just days after putting trials on hold following a series of patient deaths. Based in New York state, Acorda said ...

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

Open-Label Extension Study

The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an ...

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in subjects who previously participated in ...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1170 Associated Companies listed on BioPortfolio]

Acorda Therapeutics

Acorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial develo...

Acorda Therapeutics, Inc.

Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and other nervous system disorders. The Company's marketed products ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Acorda Therapeutics" on BioPortfolio

We have published hundreds of Acorda Therapeutics news stories on BioPortfolio along with dozens of Acorda Therapeutics Clinical Trials and PubMed Articles about Acorda Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acorda Therapeutics Companies in our database. You can also find out about relevant Acorda Therapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Corporate Database Quicklinks

Searches Linking to this Company Record